Dravet Syndrome

Cannabidiol Safe, Well Tolerated in Children With Dravet Syndrome

Cannabidiol Safe, Well Tolerated in Children With Dravet Syndrome

By

Because of the small size of the study sample, the findings may be limited to this patient population and may be hard to generalize across all pediatric patients with Dravet syndrome.

Cannabidiol Under Priority Review for Treatment of Lennox-Gastaut, Dravet Syndromes

Cannabidiol Under Priority Review for Treatment of Lennox-Gastaut, Dravet Syndromes

By

The FDA has accepted for filing with Priority Review the NDA for cannabidiol as seizure treatment.

Reducing Seizure Frequency in Dravet Syndrome With Low-Dose Fenfluramine

Reducing Seizure Frequency in Dravet Syndrome With Low-Dose Fenfluramine

By

ZX008 has received Orphan Drug designation and Fast Track designation by the FDA for the treatment of Dravet syndrome.

Add-on Cannabidiol Generally Safe for Treatment-Resistant Epilepsy, Dravet, Lennox-Gastaut Syndromes

Add-on Cannabidiol Generally Safe for Treatment-Resistant Epilepsy, Dravet, Lennox-Gastaut Syndromes

By

Adverse reactions in the CBD group included decreased appetite, diarrhea, fatigue, lethargy, nasopharyngitis, pneumonia, pyrexia, rash, and somnolence.

Distinct Phenotype in Dravet Syndrome Helps Outline Treatment

Distinct Phenotype in Dravet Syndrome Helps Outline Treatment

By

In people with Dravet syndrome, language impairments increase with age, suggesting that early intervention with targeted oral motor therapies may be helpful.

VIDEO — Industry Update: Justin Gover, CEO, GW Pharmaceuticals on Epidiolex Status

VIDEO — Industry Update: Justin Gover, CEO, GW Pharmaceuticals on Epidiolex Status

By

Justin Gover, CEO of GW Pharmaceuticals, the parent company of Greenwich Biosciences, discusses the status of the company's cannabidiol product Epidiolex on the heels of positive results from several placebo-controlled trials in epileptic syndromes.

Cannabidiol Reduces Seizure Frequency in Refractory Dravet Syndrome

Cannabidiol Reduces Seizure Frequency in Refractory Dravet Syndrome

By

Results of the phase 3, placebo-controlled trial support previous findings from an expanded-access program.

VIDEO: Cannabidiol and Our Progress Towards a Treatment for Refractory Epilepsy

VIDEO: Cannabidiol and Our Progress Towards a Treatment for Refractory Epilepsy

By

Dr Elizabeth Thiele discusses the latest on cannabidiol research for the treatment of refractory epilepsy.

Cannabidiol Therapy Reduces Seizure Frequency in Dravet Syndrome

Cannabidiol Therapy Reduces Seizure Frequency in Dravet Syndrome

By

The drug has already been given Orphan Drug and Fast Track Designation for the treatment of Dravey syndrome.

Cannabidiol Effective for Reducing Seizures in Treatment-Resistant Epilepsy

Cannabidiol Effective for Reducing Seizures in Treatment-Resistant Epilepsy

By

A large, multi-center study found cannabidiol effective for the reduction of seizures

Benefits and Complications of the Ketogenic Diet for Epilepsy

Benefits and Complications of the Ketogenic Diet for Epilepsy

By

Implementing a ketogenic diet in patients with drug-resistant epilepsy could produce significant reductions in seizure frequency.

Sign Up for Free e-newsletters



CME Focus